ACS NanoBioengineeringPeer-reviewed journal article
Lymphatic endothelial cell-targeting lipid nanoparticles delivering VEGFC mRNA improve lymphatic function after injury
Eleftheria MichalakiiD, Kiyoung JeongiD, Rachel L. ChiniD, Zhiming Qi, Lauren N. LiebmaniD, Yarelis González-VargasiD, Elisa Schrader EcheverriiD, Kalina PaunovskaiD, Hiromi MuramatsuiD, Norbert PardiiD, Beth Jiron Tamburini, Zoltán JakusiD, James E. DahlmaniD, J. Brandon DixoniD
Abstract
Dysfunction of the lymphatic system following injury, disease, or cancer treatment can lead to lymphedema, a debilitating condition with no cure. Advances in targeted therapy have shown promise for treating diseases where conventional therapies have been ineffective and lymphatic vessels have recently emerged as a new therapeutic target. Lipid nanoparticles (LNPs) have emerged as a promising strategy for tissue specific delivery of nucleic acids. Currently, there are no approaches to target LNPs to lymphatic endothelial cells, although it is well established that intradermal (ID) injection of nanoparticles will drain to lymphatics with remarkable efficiency. To design an LNP that would effectively deliver mRNA to LEC after ID delivery, we screened a library of 150 LNPs loaded with a reporter mRNA, for both self-assembly and delivery in vivo to lymphatic endothelial cells (LECs). We identified and validated several LNP formulations optimized for high LEC uptake when administered ID and compared their efficacy for delivery of functional mRNA with that of free mRNA and mRNA delivered with a commercially available MC3-based LNP (Onpattro). The lead LEC-specific LNP was then loaded with VEGFC mRNA to test the therapeutic advantage of the LEC-specific LNP (namely, LNP7) for treating a mouse tail lymphatic injury model. A single dose of VEGFC mRNA delivered via LNP7 resulted in enhanced LEC proliferation at the site of injury, and an increase in lymphatic function up to 14-days post-surgery. Our results suggest a therapeutic potential of VEGFC mRNA lymphatic-specific targeted delivery in alleviating lymphatic dysfunction observed during lymphatic injury and could provide a promising approach for targeted, transient lymphangiogenic therapy. One Sentence SummaryDevelopment of a novel lymphatic endothelial cell-targeting lipid nanoparticle via in vivo screening for mRNA delivery improves lymphatic regeneration and function after injury.
- organism: mouse
- assay: multiome
- research focus: drug response / drug discovery
- approach: experimental assay
- Citations
- 8
- FWCI
- 1.92
- Field percentile
- top 13%
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Apelin-VEGF-C mRNA delivery as therapeutic for the treatment of secondary lymphedema
A. Lamaa, J. Creff, … B. Garmy-Susini·bioRxiv·Jan 5, 2023
- Biomass-derived Lignin Nanoparticles for the Sustained Delivery of Vascular Endothelial Growth Factor-C
Ahmad Mavali Zadeh, Emanuela Gatto, … Michael Jeltsch·European Journal of Pharmaceutics and BiopharmaceuticsPeer-reviewed·Sep 4, 2025
- Systemic trafficking of mRNA lipid nanoparticle vaccine following intramuscular injection generates potent tissue-specific T cell response
Christine Y. Wei, Yining Zhu, … Hai‐Quan Mao·bioRxiv·Apr 21, 2025
- Targeted delivery of mRNA to the heart via extracellular vesicles or lipid nanoparticles
Muhammad Nawaz, Benyapa Tangruksa, … Hadi Valadi·Journal of Extracellular VesiclesPeer-reviewed·Jun 1, 2026
- Langerhans Cell-targeted mRNA Delivery: A Strategy for Dose-Sparing and Enhanced Anti-Tumor Immunity
Klara Klein, Litty Johnson, … Florian Sparber·Journal of Investigative DermatologyPeer-reviewed·Apr 7, 2026
- Lipid Nanoparticle-Associated Inflammation is Triggered by Sensing of Endosomal Damage: Engineering Endosomal Escape without Side Effects
Serena Omo-Lamai, Yufei Wang, … Jacob S. Brenner·bioRxiv·Apr 16, 2024